Cosmetic medicine: Facial resurfacing and injectables

Plastic and Reconstructive Surgery

Volumn 129, Issue 1, 2012, Pages

  Nguyen, Alexander T ^a,b,c   Ahmad, Jamil ^a,b,c   Fagien, Steven ^a,b,c   Rohrich, Rod J ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b Plastic Surgery Clinic   (Canada)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ARTEFILL; BOTULINUM TOXIN A; CELLULOSE; COLLAGEN; DRUG DERIVATIVE; HYALURONIC ACID; LACTIC ACID; MANNITOL; MUSCLE RELAXANT AGENT; POLY(METHYL METHACRYLATE); POLYLACTIC ACID;

ALGORITHM; CUTANEOUS PARAMETERS; ESTHETIC SURGERY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; REJUVENATION; REVIEW;

ALGORITHMS; BOTULINUM TOXINS, TYPE A; CELLULOSE; COLLAGEN; COSMETIC TECHNIQUES; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAMUSCULAR; LACTIC ACID; MANNITOL; NEUROMUSCULAR AGENTS; NEUROTRANSMITTER AGENTS; POLYMETHYL METHACRYLATE; REJUVENATION; SKIN AGING;

EID: 84555190304     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182362c63     Document Type: Article

References (128)

1. American Society of Plastic Surgeons. National Clearinghouse of Plastic Surgery Statistics. 2010 plastic surgery procedural statistics. Available at: http://www.plasticsurgery.org/Media/Statistics.html. Accessed December 10, 2010.
2. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: A double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33:S2-S9.
3. Bailey SH, Cohen JL, Kenkel JM. Etiology, prevention and treatment of dermal filler complications. Aesthet Surg J. 2011; 31:110-121.
4. Reisman NR. Ethics, legal issues, and consent for fillers. Clin Plast Surg. 2006;33:505-510.
5. Broughton G II, Crosby MA, Coleman J, Rohrich RJ. Use of herbal supplements and vitamins in plastic surgery: A practical review. Plast Reconstr Surg. 2007;119:48e-66e.
6. Dinehart SM, Henry L. Dietary supplements: Altered coagulation and effects on bruising. Dermatol Surg. 2005;31:819-826; discussion 826.
7. Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(Suppl):299S-339S.
8. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg. 2001;27:756-758.
9. Glogau RG. Chemical peeling and aging skin. J Geriatr Dermatol. 1994;2:30-35.
10. Clark CP III. Office-based skin care and superficial peels: The scientific rationale. Plast Reconstr Surg. 1999;104:854-864; discussion 865-866.
11. Fitzpatrick RE, Goldman MP, Satur NM, Tope WD. Pulsed carbon dioxide laser resurfacing of photo-aged facial skin. Arch Dermatol. 1996;132:395-402.
12. Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. alpha- Hydroxy acid-based cosmetic procedures: Guidelines for patient management. Am J Clin Dermatol. 2000;1:81-88.
13. Herbig K, Trussler AP, Khosla RK, Rohrich RJ. Combination Jessner's solution and trichloroacetic acid chemical peel: Technique and outcomes. Plast Reconstr Surg. 2009; 124:955-964.
14. Rohrich RJ, Herbig KS. The role of modified Jessner's solution with 35% trichloroacetic acid peel. Plast Reconstr Surg. 2009;124:965-966.
15. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: Nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008;58:719-737; quiz 738-740.
16. Fischer TC, Perosino E, Poli F, Viero MS, Dreno B; Cosmetic Dermatology European Expert Group. Chemical peels in aesthetic dermatology: An update 2009. J Eur Acad Dermatol Venereol. 2010;24:281-292.
17. Rohrich RJ, Hollier LH. Chemical peels in plastic surgery. West J Med. 1995;162:538-539.
18. Moy LS, Murad H, Moy RL. Glycolic acid peels for the treatment of wrinkles and photoaging. J Dermatol Surg Oncol. 1993;19:243-246.
19. Murad H, Shamban AT, Premo PS. The use of glycolic acid as a peeling agent. Dermatol Clin. 1995;13:285-307.
20. Kligman D, Kligman AM. Salicylic acid peels for the treatment of photoaging. Dermatol Surg. 1998;24:325-328.
21. Obagi ZE, Obagi S, Alaiti D, Stevens MB. TCA-based blue peel: A standardized procedure with depth control. Dermatol Surg. 1999;25:773-780.
22. Baker TJ. Chemical face peeling and rhytidectomy: A combined approach for facial rejuvenation. Plast Reconstr Surg Transplant Bull. 1962;29:199-207.
23. Stuzin JM, Baker TJ, Gordon HL. Chemical peel: A change in the routine. Ann Plast Surg. 1989;23:166-169.
24. Stuzin JM, Baker TJ, Gordon HL. Treatment of photoaging: Facial chemical peeling (phenol and trichloroacetic acid) and dermabrasion. Clin Plast Surg. 1993;20:9-25.
25. Hetter GP. An examination of the phenol-croton oil peel: Part I. Dissecting the formula. Plast Reconstr Surg. 2000;105: 227-239; discussion 249-251.
26. Hetter GP. An examination of the phenol-croton oil peel: Part II. The lay peelers and their croton oil formulas. Plast Reconstr Surg. 2000;105:240-248; discussion 249-251.
27. Hetter GP. An examination of the phenol-croton oil peel: Part III. The plastic surgeons' role. Plast Reconstr Surg. 2000; 105:752-763.
28. Hetter GP. An examination of the phenol-croton oil peel: Part IV. Face peel results with different concentrations of phenol and croton oil. Plast Reconstr Surg. 2000;105:1061-1083; discussion 1084-1087.
29. Bensimon RH. Croton oil peels. Aesthet Surg J. 2008;28: 33-45.
30. Vermeer BJ, Gilchrest BA. Cosmeceuticals: A proposal for rational definition, evaluation, and regulation. Arch Dermatol. 1996;132:337-340.
31. Truppman ES, Ellenby JD. Major electrocardiographic changes during chemical face peeling. Plast Reconstr Surg. 1979;63:44-48.
32. Bhalla M, Thami GP. Microdermabrasion: Reappraisal and brief review of literature. Dermatol Surg. 2006;32:809-814.
33. Karimipour DJ, Karimipour G, Orringer JS. Microdermabrasion: An evidence-based review. Plast Reconstr Surg. 2010;125: 372-377.
34. Bernard RW, Beran SJ, Rusin L. Microdermabrasion in clinical practice. Clin Plast Surg. 2000;27:571-577.
35. Rohrich RJ, Burns AJ. Lasers in office-based settings: Establishing guidelines for proper usage. Plast Reconstr Surg. 2002;109:1147-1148.
36. Rohrich RJ, Gyimesi IM, Clark P, Burns AJ. CO2 laser safety considerations in facial skin resurfacing. Plast Reconstr Surg. 1997;100:1285-1290.
37. Schwartz RJ, Burns AJ, Rohrich RJ, Barton FE Jr, Byrd HS. Long-term assessment of CO2 facial laser resurfacing: Aesthetic results and complications. Plast Reconstr Surg. 1999; 103:592-601.
38. Alster TS, Lupton JR. Prevention and treatment of side effects and complications of cutaneous laser resurfacing. Plast Reconstr Surg. 2002;109:308-316; discussion 317-318.
39. Fitzpatrick TB. Soleil et peau. J Med Esthet. 1975;2:33-34.
40. Roy D. Ablative facial resurfacing. Dermatol Clin. 2005;23: 549-559, viii.
41. Stuzin JM, Baker TJ, Baker TM, Kligman AM. Histologic effects of the high-energy pulsed CO2 laser on photoaged facial skin. Plast Reconstr Surg. 1997;99:2036-2050; discussion 2051-2055.
42. Stuzin JM, Baker TJ, Baker TM. CO2 and erbium:YAG laser resurfacing: Current status and personal perspective. Plast Reconstr Surg. 1999;103:588-591.
43. Narurkar VA. Nonablative fractional laser resurfacing. Dermatol Clin. 2009;27:473-478, vi.
44. Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications: A review. Dermatol Surg. 2010;36: 299-306.
45. Brightman LA, Brauer JA, Anolik R, et al. Ablative and fractional ablative lasers. Dermatol Clin. 2009;27:479-489, vi-vii.
46. Tierney EP, Kouba DJ, Hanke CW. Review of fractional photothermolysis: Treatment indications and efficacy. Dermatol Surg. 2009;35:1445-1461.
47. Bogdan Allemann I, Kaufman J. Fractional photothermolysis: An update. Lasers Med Sci. 2010;25:137-144.
48. Hunzeker CM, Weiss ET, Geronemus RG. Fractionated CO2 laser resurfacing: Our experience with more than 2000 treatments. Aesthet Surg J. 2009;29:317-322.
49. Alexiades-Armenaka M, Sarnoff D, Gotkin R, Sadick N. Multi-center clinical study and review of fractional ablative CO2 laser resurfacing for the treatment of rhytides, photoaging, scars and striae. J Drugs Dermatol. 2011;10:352-362.
50. Allergan, Inc. Botox Cosmetic (onabotulinumtoxinA) for injection (full prescribing information). Irvine, Calif: Allergan, Inc; 2009.
51. Medicis Aesthetics, Inc. Dysport, abobotulinumtoxinA (full prescribing information). Scottsdale, Ariz: Medicis Aesthetics, Inc; 2009.
52. Fagien S. Personal communication: Botox vs. Dysport, presented at the Baker-Gordon Symposium on Cosmetic Surgery, February, 2010.
53. Matarasso SL. Comparison of botulinum toxin types A and B: A bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg. 2003;29: 7-13; discussion 13.
54. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin. 2004;22:151-158.
55. Carruthers JD, Glogau RG, Blitzer A; Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: Botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies-Consensus recommendations. Plast Reconstr Surg. 2008;121(Suppl):5S-30S; quiz 31S-36S.
56. Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: A doubleblind, randomized controlled trial. Arch Dermatol. 2002;138: 510-514.
57. Klein AW. Dilution and storage of botulinum toxin. Dermatol Surg. 1998;24:1179-1180.
58. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg. 2003;29:523-529; discussion 529.
59. Pickett A. Dysport: Pharmacological properties and factors that influence toxin action. Toxicon 2009;54:683-689.
60. Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:S37-S43.
61. Carruthers J, Fagien S, Matarasso SL; Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast Reconstr Surg. 2004;114(Suppl):1S-22S.
62. Nguyen AT, Kenkel JM. Injectables. Sel Read Plast Surg. 2010;10:1-25.
63. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg. 2003;29: 549-556; discussion 556.
64. Carruthers A, Carruthers J. Botulinum toxin type A: History and current cosmetic use in the upper face. Semin Cutan Med Surg. 2001;20:71-84.
65. Fagien S. Botulinum A exotoxin for the management of platysma bands (Discussion). Plast Reconstr Surg. 1999;103: 653-655.
66. Fagien S. Extended use of botulinum toxin type a in facial aesthetic surgery. Aesthet Surg J. 1998;18:215-219.
67. Carruthers J, Carruthers A. The adjunctive usage of botulinum toxin. Dermatol Surg. 1998;24:1244-1247.
68. Hanke CW, Rohrich RJ, Busso M, et al. Facial soft tissue fillers: Assessing the state of the science conference: Proceedings report. J Am Acad Dermatol. 2011;64:S53-S65.
69. Rohrich RJ, Hanke CW, Busso M, et al. Facial soft tissue fillers conference: Assessing the state of the science. Plast Reconstr Surg. 2011;127(Suppl):22S-122e-S.
70. Carruthers A, Carruthers J. Non-animal-based hyaluronic acid fillers: Scientific and technical considerations. Plast Reconstr Surg. 2007;120(Suppl):33S-40S.
71. André P. Evaluation of the safety of a non-animal stabilized hyaluronic acid (NASHA-Q-Medical, Sweden) in European countries: A retrospective study from 1997 to 2001. J Eur Acad Dermatol Venereol. 2004;18:422-425.
72. Larsen NE, Pollak CT, Reiner K, Leshchiner E, Balazs EA. Hylan gel biomaterial: Dermal and immunologic compatibility. J Biomed Mater Res. 1993;27:1129-1134.
73. Matarasso SL, Carruthers JD, Jewell ML; Restylane Consensus Group. Consensus recommendations for soft-tissue augmentation with nonanimal stabilized hyaluronic acid (Restylane). Plast Reconstr Surg. 2006;117(Suppl):3S-34S; discussion 35S-43S.
74. Broder KW, Cohen SR. An overview of permanent and semipermanent fillers. Plast Reconstr Surg. 2006;118(Suppl): 7S-14S.
75. Weinkle SH, Bank DE, Boyd CM, Gold MH, Thomas JA, Murphy DK. A multi-center, double-blind, randomized controlled study of the safety and effectiveness of Juvéderm injectable gel with and without lidocaine. J Cosmet Dermatol. 2009;8:205-210.
76. Fagien S. Facial soft tissue augmentation with hyaluronic acid filler: Juvederm and Restylane: Practical Considerations for their use. In: Cohen S, ed. Facial Rejuvenation with Fillers: Techniques in Aesthetic Plastic Surgery. Philadelphia: Saunders; 2009.
77. Sherman RN. Sculptra: The new three-dimensional filler. Clin Plast Surg. 2006;33:539-550.
78. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): Technical considerations in soft-tissue contouring. Plast Reconstr Surg. 2006;118(Suppl):55S-63S.
79. Hamilton DG, Gauthier N, Robertson BF. Late-onset, recurrent facial nodules associated with injection of poly-Llactic acid. Dermatol Surg. 2008;34:123-126; discussion 126.
80. Drobeck HP, Rothstein SS, Gumaer KI, Sherer AD, Slighter RG. Histologic observation of soft tissue responses to implanted, multifaceted particles and discs of hydroxylapatite. J Oral Maxillofac Surg. 1984;42:143-149.
81. Sklar JA, White SM. Radiance FN: A new soft tissue filler. Dermatol Surg. 2004;30:764-768; discussion 768.
82. Alam M, Gladstone H, Kramer EM, et al. ASDS guidelines of care: Injectable fillers. Dermatol Surg. 2008;34(Suppl 1): S115-S148.
83. Flaharty P. Radiance. Facial Plast Surg. 2004;20:165-169.
84. Neuber F. Fetttransplantation. Chir Kongr Verhandl Dsch Gesellch Chir. 1893;22:66.
85. Coleman SR. Structural fat grafting. Aesthet Surg J. 1998;18: 386-388.
86. Coleman SR. Structural fat grafting: More than a permanent filler. Plast Reconstr Surg. 2006;118(Suppl):108S-120S.
87. Smith P, Adams WP Jr, Lipschitz AH, et al. Autologous human fat grafting: Effect of harvesting and preparation techniques on adipocyte graft survival. Plast Reconstr Surg. 2006;117:1836-1844.
88. Kaufman MR, Bradley JP, Dickinson B, et al. Autologous fat transfer national consensus survey: Trends in techniques for harvest, preparation, and application, and perception of short- and long-term results. Plast Reconstr Surg. 2007;119: 323-331.
89. Ersek RA, Gregory SR, Salisbury AV. Bioplastique at 6 years: Clinical outcome studies. Plast Reconstr Surg. 1997;100: 1570-1574.
90. Narins RS, Beer K. Liquid injectable silicone: A review of its history, immunology, technical considerations, complications, and potential. Plast Reconstr Surg. 2006;118(Suppl): 77S-84S.
91. Lemperle G, Romano JJ, Busso M. Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg. 2003;29:573-587; discussion 587.
92. Cohen SR, Berner CF, Busso M, et al. Five-year safety and efficacy of a novel polymethylmethacrylate aesthetic soft tissue filler for the correction of nasolabial folds. Dermatol Surg. 2007;33(Suppl 2):S222-S230.
93. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Am J Infect Control 2002;30:476-489.
94. Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg. 2008;34(Suppl 1):S92-S99.
95. Busso M, Applebaum D. Hand augmentation with Radiesse (Calcium hydroxylapatite). Dermatol Ther. 2007;20:385-387.
96. Busso M, Voigts R. An investigation of changes in physical properties of injectable calcium hydroxylapatite in a carrier gel when mixed with lidocaine and with lidocaine/epineph-rine. Dermatol Surg. 2008;34(Suppl 1):S16-S23; discussion S24.
97. Rohrich RJ, Herbig KS. Minimizing pain, maximizing comfort: A new technique for facial filler injections. Plast Reconstr Surg. 2009;124:1328-1329.
98. Lemperle G, de Fazio S, Nicolau P. ArteFill: A third-generation permanent dermal filler and tissue stimulator. Clin Plast Surg. 2006;33:551-565.
99. Ha RY, Nojima K, Adams WP Jr, Brown SA. Analysis of facial skin thickness: Defining the relative thickness index. Plast Reconstr Surg. 2005;115:1769-1773.
100. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg. 2006;118(Suppl):92S-107S.
101. Arlette JP, Trotter MJ. Anatomic location of hyaluronic acid filler material injected into nasolabial fold: A histologic study. Dermatol Surg. 2008;34(Suppl 1):S56-S62; discussion S62-S63.
102. Rohrich RJ, Ghavami A, Crosby MA. The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: Review and technical considerations. Plast Reconstr Surg. 2007; 120(Suppl):41S-54S.
103. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg. 2008;34(Suppl 1):S105-S109.
104. Rohrich RJ, Pessa JE, Ristow B. The youthful cheek and the deep medial fat compartment. Plast Reconstr Surg. 2008;121: 2107-2112.
105. Coleman KR, Carruthers J. Combination therapy with Botox and fillers: The new rejuvenation paradigm. Dermatol Ther. 2006;19:177-188.
106. Rohrich RJ, Pessa JE. The fat compartments of the face: Anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg. 2007;119:2219-2227; discussion 2228-2231.
107. Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: Treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg. 2003;29:802-809.
108. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35(Suppl 2):1672-1680.
109. Matarasso SL. Injectable collagens: Lost but not forgotten- A review of products, indications, and injection techniques. Plast Reconstr Surg. 2007;120(Suppl):17S-26S.
110. Alam M, Dover JS. Management of complications and sequelae with temporary injectable fillers. Plast Reconstr Surg. 2007;120(Suppl):98S-105S.
111. Rohrich RJ, Nguyen AT, Kenkel JM. Lexicon for soft tissue implants. Dermatol Surg. 2009;35:1605-1611.
112. Christensen L, Breiting V, Janssen M, Vuust J, Hogdall E. Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg. 2005;29:34-48.
113. Rohrich RJ, Monheit GD, Nguyen AT, Brown SA, Fagien S. Soft tissue filler complications: The important role of biofilms. Plast Reconstr Surg. 2010;125:1250-1256.
114. Friedman PM, Mafong EA, Kauver AN, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg. 2002; 28:491-494.
115. Narins RS, Jewell M, Rubin M, Cohen J, Strobos J. Clinical conference: Management of rare events following dermal fillers. Focal necrosis and angry red bumps. Dermatol Surg. 2006;32:426-434.
116. Glaich AS, Cohen JL, Goldberg LH. Injection necrosis of the glabella: Protocol for prevention and treatment after use of dermal fillers. Dermatol Surg. 2006;32:276-281.
117. Cohen JL, Brown MR. Anatomic considerations for soft tissue augmentation of the face. J Drugs Dermatol. 2009;8: 13-16.
118. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg. 2007;33:357-360.
119. Hirsch RJ, Brody HJ, Carruthers JD. Hyaluronidase in the office: A necessity for every dermasurgeon that injects hyaluronic acid. J Cosmet Laser Ther. 2007;9:182-185.
120. Hirsch RJ, Narurkar V, Carruthers J. Management of injected hyaluronic acid induced Tyndall effects. Lasers Surg Med. 2006;38:202-204.
121. Lemperle G, Gauthier-Hazan N. Foreign body granulomas after all injectable dermal fillers: Part 2. Treatment options. Plast Reconstr Surg. 2009;123:1864-1873.
122. Lemperle G, Gauthier-Hazan N, Wolters M, Eisemann- Klein M, Zimmermann U, Duffy DM. Foreign body granulomas after all injectable dermal fillers: Part 1. Possible causes. Plast Reconstr Surg. 2009;123:1842-1863.
123. Hoffmann N, Lee B, Hentzer M, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother. 2007;51:3677-3687.
124. Lambros V. The use of hyaluronidase to reverse the effects of hyaluronic acid filler. Plast Reconstr Surg. 2004; 114:277.
125. Cassuto D, Marangoni O, De Santis G, Christensen L. Advanced laser techniques for filler-induced complications. Dermatol Surg. 2009;35(Suppl 2):1689-1695.
126. American Society of Plastic Surgeons; American Society for Aesthetic Plastic Surgery. Injectables and fillers: Legal and regulatory risk management issues. Plast Reconstr Surg. 2006; 118(Suppl):129S-132S.
127. Joint ASPS & ASAPS Guiding Principles: Supervision of Non-Physician Personnel in Medical Spas and Physician Offices. ASPS Executive Committee and the ASAPS Executive Committee, October 2006. Available at: http://www. plasticsurgery.org/Documents/medical-professionals/health-policy/ guiding-principles/Joint-Medical-Spas-Guiding-Principles.pdf. Accessed November 17, 2011.
128. Centers for Disease Control and Prevention. Acute renal failure associated with cosmetic soft-tissue filler injections: North Carolina, 2007. MMWR Morb Mortal Wkly Rep. 2008; 57:453-456.